Partnering

Genmab, a biotechnology company specializing in antibody therapeutics for the treatment of cancer, has entered into a worldwide license and option agreement with Janssen Biotech, part of Johnson & Johnson,…

Iovance Biotherapeutics, a late-stage biotechnology company specializing in immunotherapies for cancer, has entered into a lease agreement to build a 136,000 square-foot cell-therapy production facility in Philadelphia, Pennsylvania for commercial…

Boehringer Ingelheim (BI) and Gubra, a provider of contract services for drug discovery and development, have entered into a collaboration and license agreement for the development of poly-agonist peptides to…

Eli Lilly and Company has entered into a licensing agreement with Centrexion Therapeutics, a late-clinical stage biopharmaceutical company, to acquire the exclusive global rights for CNTX-0290, a potential non-opioid treatment…

Roche’s Genentech has entered into a global collaboration and licensing agreement with Parvus Therapeutics, a privately held biopharmaceutical company, to develop, manufacture and commercialize Navacim therapeutics for treating autoimmune disorders,…

Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, and Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based company developing RNA interference (RNAi) therapeutics, have formed a collaboration, worth up to $1 billion, to…

Roche’s Genentech and Xencor, a Monrovia, California-based clinical-stage biopharmaceutical company, have formed a research and license agreement to develop and commercialize IL-15 cytokine therapeutics in a deal worth up to…

AbbVie and Teneobio, a Menlo Park, California-based biopharmaceutical company, and its affiliate TeneoOne, have entered into a global strategic transaction to develop and commercialize an immunotherapeutic for treating multiple myeloma.…

Otsuka Pharmaceutical and Click Therapeutics, a New York-based developer of software as prescription medical treatments, have signed a collaboration agreement, worth up to $302 million, to develop and commercialize a prescription…

Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has formed a worldwide collaboration and license agreement, worth up to $440 million, with MeiraGTx, a New York-…